|
Contents: |
A Year of Change Vioxx Withdrawal Prompts FDA Reform and Legal Battles Biogen Idec and Elan Withdraw Tysabri FDA Approves BiDil for African-American Patients Medicare Part D: Final Regulations Released and Enrollment Begins Debate Continues on Drug Reimportation Questions Arise Over Political Involvement in Drug Approval Decisions Concerns About a Flu Pandemic Increase EU Pharmaceutical Review Is Incorporated in EU Member States Reference Pricing for Statins Begins in Germany Merger Activity in Japan Increases Figure 1. Quarterly Sales of Celebrex and Bextra, 2004-2005 Figure 2. Yearly Prescription Drug Costs: Medicare Part D Compared with No Prescription Coverage Table 1. Currently Marketed Flu Vaccines and Projected U.S. Supply for the 2005-2006 Influenza Season Table 2. Select Mergers Between Japanese Companies, 2005
|
|